Zelluna Receives MHRA Approval for First-in-Human Trial of Novel TCR-NK Cell Therapy ZI-MA4-1
核心洞察
Zelluna (搜索) received positive feedback from the UK's MHRA for its allogeneic TCR-NK cell therapy ZI-MA4-1, clearing the regulatory pathway for clinical development.
The company plans to file a Clinical Trial Application by year-end 2025 and initiate first-in-human trials in 2026 at leading UK cancer (搜索) centers.
ZI-MA4-1 combines NK cell killing power with TCR precision targeting of MAGE-A4 antigen, designed to overcome limitations in solid tumor treatment.
Zelluna (搜索) ASA announced it has received positive scientific advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its lead candidate ZI-MA4-1, an allogeneic T Cell Receptor-based Natural Killer (TCR-NK) cell therapy targeting solid tumors (搜索). The regulatory feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for the therapy and supports the company's planned Clinical Trial Application (CTA) submission later this year.
The Norwegian biotechnology company is on track to file its CTA by year-end 2025, with plans to dose first patients and deliver initial safety and efficacy data in 2026. The milestone represents a significant step forward for Zelluna (搜索)'s novel "off-the-shelf" cell therapy platform designed to address current limitations in treating solid tumors (搜索).
Clinical Trial Leadership and Design
Zelluna (搜索) has appointed Professor Fiona Thistlethwaite, Medical Oncology Consultant at The Christie NHS Foundation Trust in Manchester, as the proposed Chief Investigator for the upcoming first-in-human trial. The Christie, recognized as one of Europe's leading cancer (搜索) centers and a major hub for advanced cell therapy research, will serve as the lead site for the study.
Dr. Andrew Furness at The Royal Marsden (搜索) in London will also play a central role in the trial. The Royal Marsden is globally recognized as a leader in oncology and early-phase cell therapy studies. Both investigators have contributed to shaping the trial's design and development strategy.
"I am genuinely excited to see the progress of ZI-MA4-1 into the clinic," said Professor Thistlethwaite, who serves as Medical Oncology Consultant within the Experimental Cancer (搜索) Medicines Team and Clinical Lead for the Advanced Immunotherapy and Cell Therapy Team at The Christie. "I am optimistic that the dual killing mechanism of the NK cells and tumour antigen directed TCR will provide us with the step-change that we need in the solid tumour setting to provide the required level of tumour potency whilst avoiding tumour escape."
Subject to CTA approval, the proposed Phase I trial will be an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4-1 across multiple solid tumors (搜索).
Novel Therapeutic Approach
ZI-MA4-1 represents Zelluna (搜索)'s proprietary approach to cell therapy, combining the innate killing power of Natural Killer cells with the precision targeting capabilities of T Cell Receptors. The therapy specifically targets the MAGE-A4 tumor antigen and is designed as an allogeneic, "off-the-shelf" treatment that could potentially offer broader patient accessibility compared to autologous cell therapies.
The company's platform addresses key limitations of current cell therapies, particularly in solid tumor treatment, through its dual mechanism of action and scalable manufacturing process that enables cost-effective production.
Strategic Momentum
"Receiving positive scientific advice from the MHRA is an important milestone as we prepare to bring ZI-MA4-1 into the clinic," said Namir Hassan, CEO of Zelluna (搜索). "With the involvement of world-class investigators and centres such as The Christie and The Royal Marsden (搜索), we are building strong momentum towards initiating a UK-based trial that could generate the first safety and efficacy data in 2026."
Hassan emphasized that the progress demonstrates "the talent and dedication of our team, and our shared commitment to advancing a novel, scalable and accessible 'off the shelf' cell therapy for patients with solid tumours."
The positive MHRA feedback and clinical partnerships position Zelluna (搜索) to advance its lead program through regulatory approval and into clinical testing, potentially offering a new treatment option for patients with solid tumors (搜索) who have limited therapeutic alternatives.